Kinpeygo (Budesonide)

Budesonide, the active glucocorticoid in Kinpeygo, is used to manage inflammatory conditions of the gastrointestinal tract.

• Crohn’s disease: reduces intestinal inflammation and helps maintain remission.
• Ulcerative colitis: decreases colonic inflammation and supports symptom control.
• Microscopic colitis: alleviates watery diarrhea by suppressing mucosal inflammation.

• Budesonide binds to intracellular glucocorticoid receptors, forming a complex that translocates to the nucleus and interacts with glucocorticoid response elements. This modulates transcription of multiple genes, leading to decreased synthesis of pro‑inflammatory cytokines, chemokines and adhesion molecules, while increasing anti‑inflammatory proteins, thereby suppressing the inflammatory response in the gastrointestinal mucosa.

Budesonide may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Oral candidiasis: fungal infection of the mouth.
• Nausea: mild to moderate stomach upset.
• Headache: transient cranial discomfort.
• Abdominal pain: cramping or discomfort in the abdomen.
• Increased appetite: may lead to weight gain.
• Mild insomnia: difficulty falling asleep.

Serious or Rare Side Effects

• Adrenal suppression: reduced endogenous cortisol production.
• Severe infections: increased susceptibility to bacterial, viral or fungal pathogens.
• Hypersensitivity reactions: rash, angioedema or anaphylaxis.
• Osteoporosis: loss of bone mineral density with long‑term use.
• Growth retardation in children: impaired linear growth during prolonged therapy.
• Severe hyperglycemia: marked elevation of blood glucose levels.

When prescribing Budesonide, clinicians should consider several precautionary measures to ensure safe use.

• Assess adrenal function: evaluate risk of suppression before and during therapy.
• Monitor infections: watch for signs of opportunistic infections.
• Use lowest effective dose: limit exposure to systemic effects.
• Evaluate bone health: consider calcium/vitamin D supplementation in long‑term use.
• Review concomitant medications: avoid strong CYP3A4 inhibitors.
• Store at ambient temperature: keep in original container, protect from moisture.

Budesonide can interact with other medicines, affecting its metabolism or increasing adverse risk.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir): may markedly increase budesonide plasma levels.
• Live vaccines: systemic immunosuppression can reduce vaccine efficacy and increase infection risk.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, phenytoin, carbamazepine): may reduce budesonide efficacy.
• Anticoagulants (warfarin): may enhance anticoagulant effect; monitor INR.
• NSAIDs: combined use may increase gastrointestinal ulcer risk.
• Antidiabetic agents: glucocorticoid effect may raise blood glucose; adjust dose as needed.